Choose Your Location
|
![]() |
SAN FRANCISCO (Map) -
The results were presented at the American Association for Cancer
Research-National Cancer Institute-European Organization for Research and
Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular
Targets and Cancer Therapeutics in
"These results allow us to focus our clinical development plan for BSI-201
by targeting tumors types that have the greatest probability of clinical
success," said BiPar Executive Vice
BiPar researchers used the Gene Logic Inc. BioExpress(R) System database to analyze PARP-1 gene expression in all types of primary human cancer and compared the results to normal counterpart tissue. PARP expression was above the 95 percent upper confidence limit for normal tissue in ovarian cancer, intraductal breast cancer, lung cancer and uterine cancer. In contrast, prostate tumor tissue showed minimal PARP overexpression.
BSI-201 has been tested as both monotherapy and in combination with standard therapy in Phase 1 studies in patients with solid tumors. BiPar is preparing to initiate Phase 1b and Phase 2 trials of BSI-201 in several specific tumor types guided largely by gene expression data.
About PARP
PARP-1 plays a central role in cell proliferation and in DNA repair. BiPar's novel, proprietary PARP inhibitors are a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively inhibit cell proliferation and are active against a broad range of tumor types.
About BiPar Sciences
BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.
BioExpress(R) is a registered trademark of Gene Logic Inc.
|
|


